FDA signs off on pivotal trial design for NGN-401 gene therapy
Neurogene has received written agreement from the U.S. Food and Drug Administration (FDA) for a registrational trial of NGN-401, a gene therapy candidate for Rett syndrome. A registrational, or pivotal, trial is designed to provide the evidence needed to support an application for FDA approval. “We appreciate the…